Abivax SA ADR (ABVX)

Currency in USD
94.13
-4.16(-4.23%)
Closed·
92.41-1.72(-1.83%)
·
ABVX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
92.5798.50
52 wk Range
69.81148.83
Key Statistics
Prev. Close
94.13
Open
98.3
Day's Range
92.57-98.5
52 wk Range
69.81-148.83
Volume
2.64M
Average Volume (3m)
1.43M
1-Year Change
14.0279%
Book Value / Share
5.24
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABVX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
164.00
Upside
+74.23%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings downwards for the upcoming period

Abivax SA ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

12 Buy
0 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 164.00
(+74.23% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Truist Securities
Buy151.00+60.42%155.00Maintain22/09/2026
Goldman Sachs
Buy155.00+64.67%-New Coverage09/09/2026
Morgan Stanley
Buy180.00+91.22%132.00Maintain24/07/2026
Piper Sandler
Buy175.00+85.91%165.00Maintain09/07/2026
Truist Securities
Buy155.00+64.67%135.00Maintain02/07/2026

Earnings

Latest Release
21/09/2026
EPS / Forecast
-1.68 / -0.60
Revenue / Forecast
1.37M / --
EPS Revisions
Last 90 days

ABVX Income Statement

Compare ABVX to Peers and Sector

Metrics to compare
ABVX
Peers
Sector
Relationship
P/E Ratio
−17.7x−2.6x−0.4x
PEG Ratio
0.27−0.080.00
Price/Book
19.4x0.1x2.6x
Price / LTM Sales
1,519.2x14.6x3.1x
Upside (Analyst Target)
74.2%176.3%55.6%
Fair Value Upside
Unlock3.9%7.8%Unlock

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
15.67M17.98%1.47B
Other Institutional Investors
93.64M82.02%8.81B
Public Companies & Retail Investors
0.000.00%0.00
Total
109.3M100.00%10.29B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
TCG Crossover Management, LLC6.89%6,007,834565,517
TCG Crossover Fund I, L.P.5.65%4,924,377463,532

People Also Watch

81.40
ABVX
-2.86%
282.12
PRAX
-6.16%
93.44
DNTH
-4.99%
7.44
ALMS
-8.26%
36.56
XENE
-6.47%

FAQ

What Is the Abivax ADR (ABVX) Stock Price Today?

The Abivax ADR stock price today is 94.13 USD.

What Stock Exchange Does Abivax ADR Trade On?

Abivax ADR is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Abivax ADR?

The stock symbol for Abivax ADR is "ABVX."

What Is the Abivax ADR Market Cap?

As of today, Abivax ADR market cap is 8.07B USD.

What Is Abivax ADR's Earnings Per Share (TTM)?

The Abivax ADR EPS (TTM) is -5.18.

When Is the Next Abivax ADR Earnings Date?

Abivax ADR will release its next earnings report on 14/12/2026.

From a Technical Analysis Perspective, Is ABVX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Abivax ADR Stock Split?

Abivax ADR has split 0 times.

How Many Employees Does Abivax ADR Have?

Abivax ADR has 98 employees.

What is the current trading status of Abivax ADR (ABVX)?

As of 24/09/2026, Abivax ADR (ABVX) is trading at a price of 94.13 USD, with a previous close of 94.13 USD. The stock has fluctuated within a day range of 92.57 USD to 98.50 USD, while its 52-week range spans from 69.81 USD to 148.83 USD.

What Is Abivax ADR (ABVX) Price Target According to Analysts?

The average 12-month price target for Abivax ADR is 164.00 USD, with a high estimate of 181 USD and a low estimate of 142 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +74.23% Upside potential.

What Is the ABVX Premarket Price?

ABVX's last pre-market stock price is 92.41 USD. The pre-market share volume is 32,650.00, and the stock has decreased by -1.72, or -1.83%.

What Is the ABVX After Hours Price?

ABVX's last after hours stock price is 93.00 USD, the stock has decreased by -1.13, or -1.20%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.